1. Effect of alirocumab on incidence of atrial fibrillation after acute coronary syndromes: insights from ODYSSEY OUTCOMES. (25th November 2020) Authors: Lopes, R; Steg, P.G; Bhatt, D.L; Bittner, V.A; Dauchy, A; Diaz, R; Goodman, S.G; Harrington, R.A; Jukema, J.W; Pordy, R; Sourdille, T; Szarek, M; White, H.D; Zeiher, A.M; Schwartz, G.G Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Lipoprotein(a) and the effect of alirocumab on coronary and non-coronary revascularization following acute coronary syndrome. (3rd October 2022) Authors: Steg, P; Szarek, M; Valgimigli, M; Islam, S; Zeiher, A M; Bhatt, D L; Bittner, V A; Diaz, R; Goodman, S G; Harrington, R A; Jukema, J W; Pordy, R; Scemama, M; White, H D; Schwartz, G G Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗